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Ovarian cancer is a common cause of cancer mortality in women with limited treatment eﬀectiveness in advanced stages. The
limitation to treatment is largely the result of high rates of cancer recurrence despite chemotherapy and eventual resistance to
existing chemotherapeutic agents. The objective of this paper is to review current concepts of ovarian carcinogenesis. We will
review existing hypotheses of tumor origin from ovarian epithelial cells, Fallopian tube, and endometrium. We will also review
the molecular pathogenesis of ovarian cancer which results in two speciﬁc pathways of carcinogenesis: (1) type I low-grade tumor
and (2) type II high-grade tumor. Improved understanding of the molecular basis of ovarian carcinogenesis has opened new
opportunities for targeted therapy. This paper will also review these potential therapeutic targets and will explore new agents that
are currently being investigated.
1.Introduction
Ovarian cancer is the most common cause of gynecologic
neoplasmandistheﬁfthcauseofcancermortalityinwomen.
The high mortality rate in women with epithelial ovarian
cancer (EOC) is due to its detection at advanced stages. Even
though there have been improvements in surgical techniques
and treatment options, ﬁve-year survival for stage III and IV
ovarian cancer still remains at approximately 45% [1].
Known risk factors of EOC include nulliparity, early me-
narche, late menopause, and age. A particularly signiﬁcant
risk factor is a strong family history of breast and ovarian
cancer. 10%–15% of women with ovarian cancer have ge-
netic predispositions of BRCA1 and BRCA 2 mutations [2].
BRCA1 is associated with a 40% lifetime risk of ovarian
cancer, and BRCA 2 has an approximately 15% lifetime risk
of ovarian cancer. Epidemiological studies show a reduction
in the incidence of EOC in developed countries [2].
Part of the complexity of EOC lies in its heterogeneity.
EOC can be classiﬁed into diverse group of tumors on the
basis of morphology and molecular genetic features. This
paperwillreviewthecurrentunderstandingofthemolecular
and morphologic heterogeneity of EOC as well as possible
explanations of pathogenesis that contribute to the hetero-
geneity.
2. Tumor Origin andPathogenesis
EOC origins are diﬃcult to ascertain, because the majority
of cases are diagnosed at late stages. Thus, there are limited
records regarding early-stage disease. Historically, EOC is
thought to originate from the ovarian epithelial surface
and undergoes progressive dediﬀerentiation and spreads to
the pelvic and abdominal cavities prior to metastasizing to
distant organs [2, 3]. However, EOC which predominantly
consists of serous, endometrioid, and mucinous cell types is
morphologically columnar and ciliated, similar to Mullerian
epithelial cell lining of the endometrium, endocervix, fallop-
ian tube, and gastrointestinal tract[3].The ovarian epithelial
surface, where these cells are purported to have originated
from, consists of a single mesothelial layer of cells that are
ﬂattened and squamous-like. To explain this discrepancy,
the traditional theories suggest that the mesothelial lining of
the ovary invaginates to form paraovarian cysts that acquire2 Journal of Oncology
Mullerian cell lining features and undergo malignant trans-
formation [4]. The enlarging tumor envelops the ovary and
is diagnosed as an adnexal mass of ovarian origin [5, 6].
Increasing evidence now suggests that the Fallopian
tube may be an alternative site of tumor origin in many
diagnosed as primary EOC [5]. In older studies, the origin
of EOCs were presumed to be the ovaries, and Fallopian
tubes were typically not examined. However, more recently,
observational studies have shown that in situ and early
invasive tubal carcinomas occur in women with a genetic
predispositionforovariancancer[5,7,8].Furthermore,over
70% of nonhereditary ovarian cancer and peritoneal high-
gradeserouscarcinomasrevealedserousepithelialcarcinoma
in the Fallopian tube and mucosal tubal involvement [9].
The ﬁmbria of the Fallopian tube are abundant with
angiolymphatic vasculature and are in direct contact with
the basement membrane of the Fallopian tube. Through
this vasculature, the serous tubal intraepithelial carcinoma
may conceivably disseminate to the surface of the ovary and
peritoneum without invasive growth from the Fallopian tube
[10, 11]. Therefore, rather than the tumor originating from a
cyst that developed from the mesothelial lining of the ovary,
tubal epithelium may directly implant into the surface of the
ovary to form an inclusion cyst which subsequently develops
into tubal epithelial carcinoma [3, 10]. An alternative pos-
sibility is that normal tubal intraepithelial cells implant into
the ovary at the time of ovulation and develop into inclusion
cysts that transform into carcinoma over time [4, 10].
Similarly, the endometrioid and clear cell carcinomas are
thought to originate from endometriosis. According to this
theory, endometrial cells “escape” the uterus via retrograde
menstrual ﬂow and implant the ovary or pelvic cavity sec-
ondarily. This mechanism has been supported by multiple
morphologic and molecular studies [12, 13].
3. Morphologic and MolecularCharacteristics
EOC was initially categorized into invasive serous carcinoma
and serous borderline tumor (SBT) which was deﬁned as a
low malignant potential carcinoma lacking invasive growth.
More recently, SBT was further subdivided into (1) atypical
proliferative serous tumor (APST) and (2) micropapillary
serous carcinoma (MPSC), a possible precursor to low-grade
serous carcinoma (LGSC) [10]. Previously, serous carcinoma
was thought be a spectrum of disease, where LGSC pro-
gressed to high-grade serous carcinoma (HGSC) over time.
However,withtheunderstandingthatLGSCarisesfromSBT,
high-grade invasive carcinoma is thought to be a disparate
entity.Thisresultedinamodelofovariancarcinogenesisthat
consists of two distinct pathways and subtypes [3, 4, 14].
The two subtypes are low-grade (type I) and high-grade
(type II). Type I tumors are typically indolent, slow growing
tumors that are often detected at early stages. Type I tumors
includelow-gradeserous,low-gradeendometrioid,clearcell,
and mucinous carcinomas [15, 16]. Type II includes high-
grade serous, high-grade endometrioid, mixed mesodermal
(carcinosarcoma), and undiﬀerentiated carcinomas. Type
II tumors are typically diagnosed in advanced stages. The
majority of EOC, approximately 75%, are type II aggressive
tumors [17, 18] .T y p eIt u m o r sh a v eam e d i a ns u r v i v a lo f8 1
months compared to 57 to 65 months in type II tumors.
Molecular and genetic diﬀerences are now being recog-
nized to further understand the distinction between these
two subtypes. The main genetic diﬀerence between the two
subtypes that explains duality in their malignant potentials
is (1) type I tumors have genetically stable and isolated
mutations and (2) type II tumors have signiﬁcant genetic
instability and involve p53 mutations that result in a more
aggressive and invasive phenotypic expression [4].
Mutational analysis and genetic expression studies have
shown that APST, MPSC, and LGSC share molecular muta-
tions that are signiﬁcantly diﬀerent from molecular alter-
ations in HGSC [10]. Type I tumors typically involve muta-
tions in a number of genes such as KRAS, BRAF, PTEN,
PIK3-CA, and CTNNB1 which encodes beta-catenin [10,
14]. Mutations in these upstream regulators result in con-
stitutive activation of the MAPK signaling pathway. Up
to 70% of MPSC and LGSC have been shown to express
active MAPK signaling [4, 15]. Her2/neu mutations have
been detected in approximately 10% of Type I tumors and
appear to be mutually exclusive with having KRAS and
BRAF mutations [10, 15]. Type I tumors rarely express p53
mutations. Furthermore, to further explain the phenotypic
association between LGSC and MPSC that are not shared
with APST, MPSC is more molecularly similar to LGSC
than APST. On the basis of mutational analysis of clear cell
carcinomas, the PI3K/PTEN pathway appears to be the most
commonly deregulated [19]. While PTEN mutations are
presentinlow-gradeendometrioidhistologies,theyalsohave
alterations in the Wnt/β-catenin pathways and CTNNB1
mutations[20].Therefore,amongthetypeItumorsubtypes,
variable genetic alterations have been identiﬁed that explain
their phenotypic diﬀerences.
In contrast, type II tumors have TP 53 mutations in up
to 95% of the cases. They are also characterized by genetic
instability and high frequencies of DNA copy number gains
and losses. They rarely contain KRAS and BRAF mutations.
A recent publication in Nature identiﬁed 9 signiﬁcantly
mutated genes in high-grade serous ovarian cancer. The
most common were RB1 mutations (67%), TP 53 mutations
(96%), PI3/Ras pathways (47%), and BRCA 1 or 2 mutations
(22%) [21]. De novo, nonfamilial cases of BRCA1 and
BRCA2 inactivation are often associated with hypermethy-
lation. In a genomic analysis of high-grade ovarian cancer,
11% of BRCA1 silencing was the result of hypermethylation
and epigenetic modiﬁcation rather than mutations. Studies
have shown that mutated or hypermethylated BRCA carriers
respond to PARP inhibitor therapy [22, 23].
4. MicroRNA
MicroRNAs are short nucleotide sequences that are noncod-
ingRNAsthatareinvolvedintheregulationofposttranscrip-
tional genes. MicroRNAs are critical in cell development but
may also contribute to tumor origin [24–27]. MicroRNAs
have been found to be diﬀerentially expressed between
ovarian carcinoma compared to normal ovarian epithelial
cells [28]. Upregulation or downregulation of microRNAJournal of Oncology 3
that regulate oncogenes and tumor suppressor genes, respec-
tively, can induce malignant transformation. Dysregulation
of microRNA expression has been associated with high-
grade serous ovarian carcinoma. The relationship between
such microRNA dysregulation and BRCA 1 or 2 expres-
sion is being explored [28]. Furthermore, microRNA have
previously been found to regulate cellular diﬀerentiation
[29, 30] and may play a role in epithelial to mesenchy-
mal cell transformation during carcinogenesis of ovarian
epithelial cells. Exploration of microRNA involvement in
ovarian carcinogenesis has recently focused attention on Let-
7 microRNA and HMGA2 gene regulation.
5.HMGA2andLet-7
HMGA2, a high-mobility-group AT-hook protein, is a non-
histone DNA-binding factor that attaches to AT-rich sequen-
ces in the minor groove of the DNA helix. It is an important
regulator of cell growth, diﬀerentiation, apoptosis, and ma-
lignant transformation. HMGA2 expression is regulated by
the microRNA Let-7. Preclinical studies have evaluated the
role of let-7 as a tumor suppressor gene to the oncogenic
mechanism of HMGA2 [31]. When the let-7 activity is
downregulated, HMGA2 activity is no longer repressed
and contributes to malignant transformation [31]. HMGA2
overexpression has been identiﬁed in 65% of ovarian carci-
noma but are rarely expressed in normal ovarian epithelial
cells [32–34]. Furthermore, HMGA2 overexpression has
been associated with high-grade serous ovarian carcinoma
[32, 33]. The Let-7 HMGA2 dysregulation may be a key
factor in ovarian carcinogenesis distinguishing low-grade or
type I from high-grade or type II EOC [35].
In our institution, we compared the HMGA2 expression
in serous OC and endometrioid OC surgical specimens. In
this study, we attempted to distinguish expression patterns
on the basis of the phenotypic grade of the OC. Fourteen
consecutive endometrioid OC were analyzed and twelve
consecutive high-grade serous carcinomas were analyzed
for HMGA2 expression by immunohistochemical staining.
High-grade serous carcinoma was associated with greater
HMGA2 expression compared to endometrioid OC. Lon-
gitudinal evaluation is pending to evaluate the prognostic
signiﬁcance of HMGA2 expression and clinical outcome
[41].
Other studies have further evaluated the correlation of
HMGA2 overexpression and p-53 mutations [32] further
demonstrating the tumorigenesis of type II high-grade EOC
that is distinct from type I low-grade EOC. Furthermore,
animal models have shown that HMGA2 silencing is associ-
atedwithreductionintumorgrowthandincreasedapoptosis
of tumor cells [34]. This suggests that HMGA2 may be a
possible target in ovarian cancer therapy.
6. Opportunitiesfor Targeted Therapy
Despite optimal surgical and cytotoxic treatment of ad-
vanced ovarian cancer, only 10% to 15% achieve long-
term remission, and the majority will face recurrent disease
[42, 43]. While there is a role for chemotherapy in recurrent
disease, the eﬀects are often short lived due to development
ofchemoresistance[44].Targetedtherapiesinovariancancer
are currently being investigated to ﬁnd novel ways to over-
come chemoresistance. These molecular targets of therapy
include: VEGF (antiangiogenesis), EGFR tyrosine kinase,
HER2 receptor, PARP, and MAPK/BRAF/MEK pathways
(See Table 1).
7. Antiangiogenesis
Angiogenesis has been shown to be a key component in
ovarian cancer metastasis and ascites development [45].
Vascular endothelial growth factor (VEGF) is a critical
regulator of angiogenesis and is involved in various aspects
of ovarian carcinogenesis [46]. Antiangiogenic therapy has
been shown to have activity in ovarian cancer. Bevacizumab
is a monoclonal antibody that targets VEGF-A. Two phase
II trials with single-agent bevacizumab have shown 16%
to 21% response [47, 48]. Phase III studies involving
chemotherapy with or without bevacizumab presented dur-
ing the 2011 Annual Meeting of the American Society of
Clinical Oncology (ASCO) showed a trend toward an overall
survival beneﬁt in patients treated with bevacizumab in
addition to chemotherapy in the ﬁrst line setting with HR =
0.64 P = 0.0022 in those with poor prognosis disease
(ICON7). Similar data were reported in patients treated for
platinum sensitive recurrent ovarian cancer with median
overall survival of 35.5 months (+bevacizumab) versus 29.9
months (−bevacizumab) and HR = 0.751 P = 0.094
(OCEANS) [49].
Mammalian target of rapamycin (mTOR) is involved in
cell growth and proliferation and induces increases in VEGF
and platelet derived growth factor (PDGF) that ultimately
activate angiogenesis. mTOR inhibitors have also shown
single agent activity in the treatment of clear cell ovarian
carcinoma [50]. The antiangiogenic eﬀects are thought to
be synergistic with that of bevacizumab. Results of a phase
II study combining the mTOR inhibitor, temsirolimus, with
bevacizumab suggest possible synergy [49]. Other phase I
and II trials involving antiangiogenic therapy are showing
activityassingleagentsorsynergisticallywithchemotherapy.
These agents include (1) VEGF trap (Aﬂibercept) which
is a fusion protein that acts as a high-aﬃnity VEGF
receptor blocker, (2) Sunitinib (a PDGF and VEGF receptor
inhibitor), (3) Vatalanib (a pan-VEGF receptor inhibitor),
(4) Motesanib (a multikinase inhibitor of PDGF, VEGF, and
cKIT), and (5) Cedarinib (a VEGF tyrosine kinase receptor
inhibitor).
8. Anti-HER2Therapy
Her2 expression in ovarian cancer has been variable. Many
studies evaluate HER2 expression in ovarian cancer as a
positive or negative expression and do not describe the
staining intensity to characterize the overexpression of HER2
[51]. The studies that have evaluated HER2 overexpression
demonstrate signiﬁcant variability in intense HER2 staining
from 1.8% to 35% [43, 51–53]. Studies have suggested that
gene ampliﬁcation does not always correlate with HER24 Journal of Oncology
Table 1: Potential targets of therapy in ovarian cancer.
Targets Inhibitors Studies NCI study
GOG 218
VEGF Bevacizumab Phase III [49]I C O N 7
GOG 213
OCEANS
VEGF TKI
Sunitinib Phase II
NCT00979992
NCT00768144
NCT00388037
Vatalanib Phase I (+doce) NCT00268918
Sorafenib
Phase II (+carb/pacli) NCT00390611
Phase II (+topo) NCT01047891
Phase II NCT00522301
Phase II (+bev) NCT00436215
Phase II [36] NCT00093626
Phase II (+carb/pacli) NCT00096200
Vandetanib
Phae I/II (+bortezomib) NCT00923247
Phase II NCT00445549
Phase II(+/− doce) NCT00872989
Cediranib
Phase I/II(+olaparib) NCT01116648
Phase II NCT00275028
Phase II (+temsirolimus) NCT01065662
Pazopanib
Phase I/II (+cyclophosphamide) NCT01238770
Phase II NCT01262014
Phase I/II [37] NCT01035658
Phase II NCT00281632
Phase III NCT00866697
Vargatef Phase I (+everolimus) Pending
AMG 706 Phase II NCT00574951
VEGF TRAP Aﬂibercept Phase II NCT00327171
Phase II (+doce) NCT00436501
PI3K-PTEN-Akt-mTOR pathway
Temsirolimus
Phase I (+lip Doxo) NCT00982631
Phase II NCT00926107
Phase II (carb/pacli) NCT01196429
Phase II NCT00429793
Phase I/II(+bev) NCT01010126
Everolimus
Phase II (+bev) NCT01031381
Phase II (+/− bev) NCT00886691
Phase II (+lip doxo) NCT01281514
Ridaforolimus Phase I (+carb/pacli) NCT01256268Journal of Oncology 5
Table 1: Continued.
Targets Inhibitors Studies NCI study
EGFR
Cetuximab Phase II (carb/pacli) NCT00063401/
Phase II (+carb) NCT00086892
Erlotinib
Phase II (+bev) [38] NCT00130520
Phase II (+topo) NCT01003938
Phase I/II (+carb/pacli) NCT00217529
Phase II (+carb) NCT00030446
Phase II (+bev after carb/pacli/bev) NCT00520013
Lapatinib
Phase II (+topo) [39] NCT00436644
Phase II NCT00113373
Phase I/II (+carb/pacli) NCT00316407
HER2
Trastuzumab Phase II [40]
Pertuzumab Phase II NCT00058552
Phase II (+gemcitabine) NCT00096993
Lapatinib See above
PARP
ABT 888
Phase II (+temoz versus lip doxo) NCT01113957
Phase II (+cyclophosphamide) NCT01306032
Phase I/II (+topo) NCT01012817
Phase I (+carb/pacli/bev) NCT00989651
Olaparib
Phase II (+carb/pacli) NCT01081951
Phase I (+carb) NCT00647062
Phase II NCT00679783
Phase II NCT00494442
Phase II (versus lip doxo) NCT00628251
Phase II NCT00753545
Phase II NCT01033123
Iniparib∗ Phase II (carb/gemcitabine) NCT01033292
Phase II NCT00677079
Epigenetic
Decitabine Phase II (+carb) NCT00477386
Phase I (+doxorubicin/vaccine) NCT00887796
Belinostat Phase I/II (+carb or pacli) NCT00421889
MAPK/RAF/MEK pathway Cabozantinib Phase I NCT00940225
HMGA2 Let-7 microRNA Preclinical
∗Iniparib as a true PARP inhibitor is currently under investigation.
Doce: docetaxel, Carb: carboplatin, pacli: paclitaxel, topo: topotecan, bev: bevacizumab, temoz: temozolomide, and lip doxo: liposomal doxorubicin.
protein overexpression [54].Furthermore,somedatasuggest
that HER2 overexpression is mostly found in high-grade
serous histology as opposed to low-grade endometrioid
[55]. Her2 positive expression has demonstrated association
with survival in patients with EOC [53, 56–58]. More
recently, HER2 gene status was evaluated from the GINECO
study, and no survival diﬀerences were detected in patients
with or without HER2 overexpression who were treated
with carboplatin/paclitaxel [59]. This suggests an association
between HER2 status and paclitaxel sensitivity.
As a result of such variability in HER2 expression in
ovarian cancer, the role of anti-HER2 therapy is unclear.
Anti-HER2 therapy with trastuzumab and pertuzumab have
shown modest activity in ovarian cancer [40, 60]. Preclinical
studies initially suggested activity in tumors without HER2
overexpression [61]. However, subset analyses of phase II
trials indicate that pertuzumab has better activity in those
with HER2 overexpression [60]. HER2 expression in EOC
has not been studied as extensively as in breast cancer, and
there are many inconsistent data. Thus, the limitations to6 Journal of Oncology
anti-HER2 therapy hinges on further careful examination
of HER2 oncogene as a potential prognostic, predictive, and
therapeutic target.
9.EGFRTyrosineKinaseInhibitors
EGFR tyrosine kinase inhibitors are also being explored
including cetuximab, lapatinib, and erlotinib [62, 63]. A
phase II study of erlotinib with carboplatin has shown
activity in platinum sensitive recurrent ovarian cancer (57%
objective response rate in platinum sensitive and 7% in
platinum-resistant patients) [64]. A phase II study with
erlotinib, carboplatin, and paclitaxel in the ﬁrst line set-
ting showed no statistically signiﬁcant pathologic complete
response rates compared to historical controls [65]. A Phase
I/II study of lapatinib with carboplatin and paclitaxel in
recurrent stage III or IV ovarian and breast cancer proved
safe with favorable response rates [66]. Recently, a phase
II study was published which explored lapatinib combined
with topotecan in platinum refractory or resistant ovarian
cancer. This study showed minimal clinical activity with
signiﬁcant hematologic grade 3 and 4 toxicities [39]. A Phase
II study with cetuximab and carboplatin in EGFR-positive
ovariancancershowedmodestactivitywhere9of28patients
achieved objective response and 8 of 28 patients had stable
disease [67]. Toxicities in this study included acneiform rash
and hypersensitivity reactions. Another phase II study with
cetuximab, carboplatin, and paclitaxel failed to demonstrate
progression-free survival beneﬁt compared to historical data
[62].
10.PARPInhibitors
Poly (ADP-ribose) polymerase (PARP) inhibitors block base
excisionrepair.FortumorsthatlackDNArepairmechanisms
due to BRCA1/BRCA2, HNPCC, Fanconi Anemia, and other
genetic mutations, inhibiting alternate repair pathways with
PARP inhibition may increase antitumor selectivity and
improve chemotherapy sensitivity. Three phase II studies
with PARP inhibitors, olaparib and iniparib, show activity in
recurrent platinum sensitive ovarian cancer in combination
with chemotherapy or as single-agent maintenance after
chemotherapy [49]. Olaparib as a maintenance therapy has
also been shown to improve progression-free survival by 3.6
months compared to placebo in platinum-sensitive relapsed
serous ovarian cancer. (ASCO 2011 abstract 5003) There
is currently an ongoing NCI sponsored randomized Phase
II study that explores ABT 888 (veliparib) with cyclophos-
phamide in BRCA positive ovarian and triple negative breast
cancer [68].
11.Epigenetic Studies
The pathophysiology of cancer is not only the result of inher-
ited or sporadic genetic mutations but is also the result of
epigenetic modiﬁcations in the genome. Histone hypoacety-
lation and abnormal DNA methylation also contribute to
tumorigenesisandchemotherapyresistance.AphaseIIstudy
with the DNA hypomethylating agent, decitabine, showed
improved response rates in platinum-resistant ovarian can-
cer when added to carboplatin therapy at low dosages, where
9outof17patientshadprogression-freesurvivalat6months
(ASCO 2011 abstract 5011) [49]. Other studies with the
histone deacetylase inhibitor, belinostat, and the proteosome
inhibitor, carﬁlzomib, are being explored in ongoing phase II
trials.
12. MAPK/BRAF/MEK Pathway
One of the major pathways that regulate cellular growth
is extracellular-related kinase (ERK) which triggers a cell
surface-receptor mediated signaling cascade involving Ras,
Raf, MEK [mitogen-activated protein (MAP)/ERK kinases]
and ERK. As described previously, BRAF mutations are
commonly associated with low-grade ovarian carcinoma.
BRAF mutations result in the constitutive activation of
the MAP kinase/MEK pathways. Furthermore, preclinical
models have shown that in addition to BRAF mutations in
low-grade tumors, Raf-1 isoform predominantly mediates
ovarian cancer cell growth compared with Raf-A or B-Raf
isoforms [69]. There have also been reports demonstrating
reduced survival in ovarian cancer patients with increased
expression of Raf-1 [70]. Thus, the MAPK/BRAF/MEK
pathway can be a target in both high-grade and low-grade
ovarian cancer. MET tyrosine kinase cell surface receptor
is involved in RAF and MAP kinase activation pathways,
and its inhibition results in downstream suppression of
RAF and MAP kinase activity. The potent MET inhibitor,
cabozantinib, showed activity in advanced ovarian cancer
irrespective of platinum sensitivity [49].
13. Let-7 MicroRNA Therapy
Among the emerging next-generation therapies are the
microRNA therapeutics. Preclinical mouse models with ex-
ogenous Let-7 microRNA have shown suppression of cell
proliferation in breast cancer cells [71, 72]. There are sig-
niﬁcant limitations to clinical applicability of microRNA
technology at this time due to a limited understanding of the
Let-7 mechanism and with methods of delivery.
14. Conclusion
Epithelial ovarian carcinoma is a highly heterogeneous dis-
ease process that is associated with signiﬁcant mortality
and morbidity. Recent progress in molecular characteristics
of ovarian cancer has helped delineate the origins of
carcinogenesis, particularly, a model of tumorigenesis which
is based on a dichotomous theory of (1) low-grade or
type I ovarian cancer associated with gene stability and
multiple isolated mutations and (2) high-grade type II
ovarian cancer associated with genetic instability and p53
mutations. Continued evaluation of the molecular makeup
of ovarian carcinoma is critical in the further identiﬁcation
of treatment targets and improved clinical outcome.Journal of Oncology 7
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